These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37959379)

  • 21. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.
    Pradhan AD; Paynter NP; Everett BM; Glynn RJ; Amarenco P; Elam M; Ginsberg H; Hiatt WR; Ishibashi S; Koenig W; Nordestgaard BG; Fruchart JC; Libby P; Ridker PM
    Am Heart J; 2018 Dec; 206():80-93. PubMed ID: 30342298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case report: a potential modulation of coronary atheroma by lowering triglyceride-rich lipoproteins with pemafibrate: insights from serial near-infrared spectroscopy imaging.
    Murata Y; Kataoka Y; Asaumi Y; Noguchi T
    Cardiovasc Diagn Ther; 2023 Feb; 13(1):100-108. PubMed ID: 36864976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.
    Yokote K; Yamashita S; Arai H; Araki E; Suganami H; Ishibashi S; Of The K-Study Group OB
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30736366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.
    Iitake C; Masuda D; Koseki M; Yamashita S
    Cardiovasc Diabetol; 2020 Nov; 19(1):201. PubMed ID: 33246467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
    Ishibashi S; Arai H; Yokote K; Araki E; Suganami H; Yamashita S;
    J Clin Lipidol; 2018; 12(1):173-184. PubMed ID: 29203092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.
    Araki E; Yamashita S; Arai H; Yokote K; Satoh J; Inoguchi T; Nakamura J; Maegawa H; Yoshioka N; Tanizawa Y; Watada H; Suganami H; Ishibashi S
    Diabetes Care; 2018 Mar; 41(3):538-546. PubMed ID: 29298800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study.
    Nakamura A; Kagaya Y; Saito H; Kanazawa M; Sato K; Miura M; Kondo M; Endo H
    J Atheroscler Thromb; 2023 May; 30(5):443-454. PubMed ID: 35768226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients.
    Yanai H; Katsuyama H; Hakoshima M
    Cardiol Res; 2021 Dec; 12(6):358-362. PubMed ID: 34970366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study.
    Ide K; Koshizaka M; Tokuyama H; Tokuyama T; Ishikawa T; Maezawa Y; Takemoto M; Yokote K
    Lipids Health Dis; 2018 Mar; 17(1):51. PubMed ID: 29544483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis.
    Yamashita S; Rizzo M; Su TC; Masuda D
    Metabolites; 2023 May; 13(5):. PubMed ID: 37233667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study.
    Kito K; Nomoto H; Sakuma I; Nakamura A; Cho KY; Kameda H; Miya A; Omori K; Yanagiya S; Handa T; Taneda S; Takeuchi J; Nagai S; Yamashita K; Kurihara Y; Atsumi T; Miyoshi H;
    Diabetes Res Clin Pract; 2022 Oct; 192():110091. PubMed ID: 36174777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia.
    Yamashita S; Arai H; Yokote K; Araki E; Suganami H; Ishibashi S;
    J Clin Lipidol; 2018; 12(5):1267-1279.e4. PubMed ID: 30077640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.
    Yamashita S; Masuda D; Matsuzawa Y
    J Atheroscler Thromb; 2019 May; 26(5):389-402. PubMed ID: 30930344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor α modular (SPPARMα), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury.
    Konishi H; Miyauchi K; Onishi A; Suzuki S; Fuchimoto D; Shitara J; Endo H; Wada H; Doi S; Naito R; Ogita M; Dohi T; Kasai T; Daida H
    PLoS One; 2020; 15(11):e0241195. PubMed ID: 33201888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia.
    Tanaka A; Nakamura T; Sato E; Chihara A; Node K
    CEN Case Rep; 2020 May; 9(2):141-146. PubMed ID: 31950425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study.
    Yanai H; Katsuyama H; Hakoshima M
    Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimation of Small Dense LDL-Cholesterol Levels in Patients with Acute Coronary Syndrome.
    Imamura T; Narang N; Hori M; Kinugawa K
    Int Heart J; 2023; 64(4):596-601. PubMed ID: 37518340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pemafibrate, A Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Reduces Plasma Eicosanoid Levels and Ameliorates Endothelial Dysfunction in Diabetic Mice.
    Suto K; Fukuda D; Shinohara M; Ganbaatar B; Yagi S; Kusunose K; Yamada H; Soeki T; Hirata KI; Sata M
    J Atheroscler Thromb; 2021 Dec; 28(12):1349-1360. PubMed ID: 33775978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and methods of an open-label, randomized controlled trial to evaluate the effect of pemafibrate on proteinuria in CKD patients (PROFIT-CKD).
    Seki M; Nakano T; Tanaka S; Matsukuma Y; Funakoshi K; Ohkuma T; Kitazono T
    Clin Exp Nephrol; 2023 Apr; 27(4):358-364. PubMed ID: 36738362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.
    Hennuyer N; Duplan I; Paquet C; Vanhoutte J; Woitrain E; Touche V; Colin S; Vallez E; Lestavel S; Lefebvre P; Staels B
    Atherosclerosis; 2016 Jun; 249():200-8. PubMed ID: 27108950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.